TrialBritish journal of haematology2010

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).

Sergio Amadori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.